Steven K Teo

Summary

Affiliation: Celgene Corporation
Country: USA

Publications

  1. ncbi request reprint Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients
    S K Teo
    Celgene Corporation, Warren, NJ 07059, USA
    J Biochem Mol Toxicol 14:140-7. 2000
  2. ncbi request reprint Thalidomide as a novel therapeutic agent: new uses for an old product
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Drug Discov Today 10:107-14. 2005
  3. ncbi request reprint Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring
    Steve K Teo
    Celgene Corp, 7 Powder Horn Drive, Warren, New Jersey 07059, USA
    Toxicol Sci 81:379-89. 2004
  4. ncbi request reprint Clinical pharmacokinetics of thalidomide
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Clin Pharmacokinet 43:311-27. 2004
  5. ncbi request reprint Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Birth Defects Res B Dev Reprod Toxicol 71:1-16. 2004
  6. ncbi request reprint D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Birth Defects Res B Dev Reprod Toxicol 68:162-71. 2003
  7. ncbi request reprint A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs
    Steve K Teo
    Celgene Corporation, Warren, New Jersey, USA
    Int J Toxicol 22:215-26. 2003
  8. ncbi request reprint D-Methylphenidate is non-genotoxic in in vitro and in vivo assays
    Steve K Teo
    Celgene Corp, Warren, NJ 07059, USA
    Mutat Res 537:67-79. 2003
  9. ncbi request reprint Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline
    Steve K Teo
    Celgene Corp, Warren, New Jersey 07059, USA
    Chirality 15:348-51. 2003
  10. ncbi request reprint Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Pharmacol Biochem Behav 74:747-54. 2003

Detail Information

Publications19

  1. ncbi request reprint Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients
    S K Teo
    Celgene Corporation, Warren, NJ 07059, USA
    J Biochem Mol Toxicol 14:140-7. 2000
    ..The major route of thalidomide breakdown in humans and animals is through spontaneous hydrolysis with subsequent elimination in the urine...
  2. ncbi request reprint Thalidomide as a novel therapeutic agent: new uses for an old product
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Drug Discov Today 10:107-14. 2005
    ..The analogue lenalidomide has shown potential in treating the bone marrow disorders multiple myeloma and myelodysplastic syndrome, and is presently in Phase II and III trials, respectively...
  3. ncbi request reprint Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring
    Steve K Teo
    Celgene Corp, 7 Powder Horn Drive, Warren, New Jersey 07059, USA
    Toxicol Sci 81:379-89. 2004
    ..No gross external changes were observed in F1 and F2 pups...
  4. ncbi request reprint Clinical pharmacokinetics of thalidomide
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Clin Pharmacokinet 43:311-27. 2004
    ..Since thalidomide is mainly hydrolysed and passively excreted, its pharmacokinetics are not expected to change in patients with impaired liver or kidney function...
  5. ncbi request reprint Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Birth Defects Res B Dev Reprod Toxicol 71:1-16. 2004
    ..The present work was performed to determine the effect of thalidomide exposure on reproductive function and early embryonic development...
  6. ncbi request reprint D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits
    Steve K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Birth Defects Res B Dev Reprod Toxicol 68:162-71. 2003
    ..The developmental toxicity of both compounds was determined and compared in rats and rabbits according to current International Conference on Harmonization (ICH) guidelines...
  7. ncbi request reprint A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs
    Steve K Teo
    Celgene Corporation, Warren, New Jersey, USA
    Int J Toxicol 22:215-26. 2003
    ..There were no abnormal clinical pathology or macroscopic or microscopic findings. Based on body weight changes, the no-observed-adverse-effect level (NOAEL) of d-MPH in beagle dogs was 3 mg/kg/day...
  8. ncbi request reprint D-Methylphenidate is non-genotoxic in in vitro and in vivo assays
    Steve K Teo
    Celgene Corp, Warren, NJ 07059, USA
    Mutat Res 537:67-79. 2003
    ..Our present results along with published epidemiological data from patient populations are consistent with the conclusion that D-MPH and D,L-MPH do not present a carcinogenic risk to humans...
  9. ncbi request reprint Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline
    Steve K Teo
    Celgene Corp, Warren, New Jersey 07059, USA
    Chirality 15:348-51. 2003
    ..In this article we report on the rapid racemization of the S-isomer of CC-4047 in human plasma and phosphate-buffered saline. These results support the further development of the racemate instead of the S-isomer...
  10. ncbi request reprint Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Pharmacol Biochem Behav 74:747-54. 2003
    ..In summary, fewer significant FOBs were seen with D- and L-MPH compared to equimolar doses of D,L-MPH. L-MPH was the least potent in producing FOBs. These results were supported by rota-rod studies...
  11. ncbi request reprint Thalidomide in the treatment of leprosy
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Microbes Infect 4:1193-202. 2002
    ..Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-alpha produced by monocytes...
  12. ncbi request reprint A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats
    Steve Teo
    Pharmacokinetics and Toxicology, Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Toxicology 179:183-96. 2002
    ..Overall, the toxicity profile observed in rats with 50 mg/kg per day D-MPH was comparable to that of an equimolar dose of D,L-MPH (100 mg/kg per day) when given repeatedly for 90 days using a twice a day dosing regimen...
  13. ncbi request reprint The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats
    Steve K Teo
    Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Reprod Toxicol 16:353-66. 2002
    ..Neither compound produced any other significant adverse findings in F0 and F1 generation rats at doses that were at least 25 times the maximum daily human therapeutic dose...
  14. ncbi request reprint Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry
    Steve K Teo
    Celgene Corporation, Warren, NJ 07059, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 767:145-51. 2002
    ..Batch sizes of 100 samples per matrix were analyzed with a total run time of 5 h. The methods successfully determined concentrations of thalidomide from a clinical study to levels as low as 7 ng/ml plasma and 8 ng/g semen, respectively...
  15. ncbi request reprint Thalidomide is distributed into human semen after oral dosing
    S K Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Drug Metab Dispos 29:1355-7. 2001
    ..Semen levels could be significantly greater for therapeutic doses of more than 100 mg/day. Since the threshold dose for birth defects and thalidomide exposure is not known, male patients are advised to use barrier contraception...
  16. ncbi request reprint Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs
    S K Teo
    Celgene Corp, 7 Powder Horn Drive, Warren, New Jersey 07059, USA
    Toxicol Sci 59:160-8. 2001
    ..There was no gross and histopathologic evidence of any tumors. In summary, thalidomide at up to 1000 mg/kg/day for 53 weeks did not induce any major systemic toxicity or tumors in dogs. The NOAEL was 200 mg/kg/day...
  17. ncbi request reprint Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women
    S K Teo
    Celgene Corporation, Warren, NJ 07059, USA
    Biopharm Drug Dispos 21:33-40. 2000
    ..5-1.5 h, but had little effect on the extent of absorption from the Celgene capsule. Under fasted conditions, the Celgene thalidomide resulted in a two-fold greater C(max) and 10% greater AUC(0-infinity) than the Serral formulation...
  18. ncbi request reprint Assessment of the in vitro and in vivo genotoxicity of Thalomid (thalidomide)
    S Teo
    Celgene Corporation, Warren, New Jersey 07059, USA
    Teratog Carcinog Mutagen 20:301-11. 2000
    ..It also did not produce any significant increase in the average mutant frequencies of AS52 cells and mouse micronucleated polychromatic erythrocytes. We conclude that Celgene's Thalomid thalidomide is non-genotoxic...
  19. pmc Properties of thalidomide and its analogues: implications for anticancer therapy
    Steven K Teo
    Celgene Corporation, Summit, NJ 07901, USA
    AAPS J 7:E14-9. 2005
    ..It is currently in phase II and III trials for these diseases respectively with numerous phase II trials in other hematologic and solid tumors...